 |
|
|
| |
The Novel FXR Agonist, EDP-305, Reduces Fibrosis Progression in Rodent Models
of Primary Biliary Cholangitis and Non-alcoholic Steatohepatitis
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Derek J. Erstad, Christian T. Farrar, Sarani Ghoshal, Lan Wei, Ji-Kyung Choi, Diego Dos Santos Ferreira, Ricard Masia,
Nicholas Rotile, Phillip A. Waghorn, Yang Li, Mary Chau, Kenneth K. Tanabe, Yat Sun Or, Peter Caravan, Lijuan Jiang and Bryan C. Fuchs
EASL: A novel farnesoid X receptor agonist: EDP-305, reduces fibrosis progression in animal models of fibrosis - (05/23/17)
EASL: Enanta Announces New Preclinical Data on its FXR Agonist EDP-305 for Non-Alcoholic Steatohepatitis (NASH) and Primary Biliary Cholangitis (PBC) at The International Liver Congress™ 2017 - (05/23/17)
EASL: EDP-305, a novel and highly potent farnesoid X receptor agonist, improves liver steatosis, ballooning and non-alcoholic fatty liver disease (NAFLD) activity score (NAS) in a diet-induced murine model of non-alcoholic steatohepatitis - (05/23/17)
|
| |
|
|
|
|
|
